REVIEW PAPER
Gastroenteropancreatic neuroendocrine tumours – an overview
1
Students’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, Poland Head of the Department: Prof. Andrzej Deptała MD, PhD
2
Department of Cancer Prevention, Medical University of Warsaw, Warsaw, Poland Head of the Department: Prof. Andrzej Deptała MD, PhD
Submission date: 2022-07-18
Final revision date: 2022-09-18
Acceptance date: 2022-09-19
Publication date: 2022-12-16
Medical Studies 2022;38(4):361-376
KEYWORDS
TOPICS
ABSTRACT
Neuroendocrine neoplasms (NENs) belong to a group of various tumours that can arise on many internal organs. Among NENs a large class of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) can be distinguished, which comprise neoplasms arising from the gastrointestinal tract and pancreas. Therefore, this review provides the current status of the World Health Organization classification of GEP-NETs as well as an overview of their clinical presentation, diagnosis, and treatment methods. GEP-NETs are generally divided into 5 groups: pancreatic NETs (PanNETs), gastric NETs (G-NETs), duodenal NETs (D-NETs), jejunoileal NETs (Je-Ile NETs), and neuroendocrine neoplasms of the large intestine. Moreover, in each group several subtypes have been introduced according to cell differentiation, mitotic rate, and Ki-67 index. Low- and intermediate-grade GEP-NETs are well differentiated, have a mitotic rate under 20, and a Ki-67 index under 20%. High-grade GEP-NETs, however, are characterized by poor differentiation, mitotic rate over 20, and Ki-67 index over 20%.
REFERENCES (131)
1.
Migut AE, Kaur H, Avritscher R. Neuroendocrine tumors: imaging of treatment and follow-up. Radiol Clin North Am 2020; 58: 1161-1171.
2.
Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia 2017; 19: 991-1002.
3.
Mittra ES. Neuroendocrine tumor therapy: (177)Lu- DOTATATE. AJR Am J Roentgenol 2018; 211: 278-285.
4.
Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2018; 68: 471-487.
5.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3: 1335-1342.
6.
Fang JM, Shi J. A clinicopathologic and molecular update of pancreatic neuroendocrine neoplasms with a focus on the new world health organization classification. Arch Pathol Lab Med 2019; 143: 1317-1326.
7.
Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L, Fanciulli G, Feola T, Baldelli R, Ruggeri RM, Gallo M, Guarnotta V, Malandrino P, Messina E, Venne- ri MA, Giannetta E, Ferone D, Colao A, Faggiano A, NIKE group. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine 2020; 69: 441-450.
8.
Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer 2014; 21: R153-R163.
9.
Ishida H, Lam AK. Pancreatic neuroendocrine neoplasms: the latest surgical and medical treatment strategies based on the current World Health Organization classification. Crit Rev Oncol Hematol 2020; 145: 102835.
10.
Guilmette JM, Nosé V. Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances. Adv Anat Pathol 2019; 26: 13-30.
11.
Assarzadegan N, Montgomery E. What is new in 2019 World Health Organization (WHO) classification of tumors of the digestive system: review of selected updates on neuroendocrine neoplasms, appendiceal tumors, and molecular testing. Arch Pathol Lab Med 2021; 145: 664-77.
12.
Bar-Moshe Y, Mazeh H, Grozinsky-Glasberg S. Non-functioning pancreatic neuroendocrine tumors: surgery or observation? World J Gastrointest Endosc 2017; 9: 153-161.
13.
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA, WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76: 182-188.
14.
Lee DW, Kim MK, Kim HG. Diagnosis of pancreatic neuroendocrine tumors. Clin Endosc 2017; 50: 537-545.
15.
Sandru F, Carsote M, Albu SE, Valea A, Petca A, Dumitrascu MC. Glucagonoma: from skin lesions to the neuroendocrine component (review). Exp Ther Med 2020; 20: 3389-3393.
16.
Sandru F, Carsote M, Valea A, Albu SE, Petca RC, Dumitrascu MC. Somatostatinoma: beyond neurofibromatosis type 1 (review). Exp Ther Med 2020; 20: 3383-3388.
17.
Guarnotta V, Martini C, Davì MV, Pizza G, Colao A, Faggiano A. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? Endocrine 2018; 60: 15-27.
18.
Sandhu S, Jialal I. ViPoma. StatPearls. Treasure Island (FL): StatPearls Publishing LLC 2020.
19.
Tsoukalas N, Chatzellis E, Rontogianni D, Alexandraki KI, Boutzios G, Angelousi A, Kaltsas G. Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): report of 5 cases and review of the literature. Medicine 2017; 96: e6201.
20.
Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018; 25: 22-35.
21.
Bleicher J, Lombardo S, Carbine S, Kapitonov D, Pletne- va MA, Mulvihill SJ. Adrenocorticotropin hormone secreting carcinoma of the pancreas: a case report. J Pancreat Cancer 2019; 5: 22-25.
22.
Maragliano R, Vanoli A, Albarello L, Milione M, Basturk O, Klimstra DS, Wachtel A, Uccella S, Vicari E, Mile- si M, Davì MV, Scarpa A, Sessa F, Capella C, La Rosa S. ACTH-secreting pancreatic neoplasms associated with Cushing syndrome: clinicopathologic study of 11 cases and review of the literature. Am J Surg Pathol 2015; 39: 374-382.
23.
Araujo Castro M, Palacios García N, Aller Pardo J, Izquierdo Alvarez C, Armengod Grao L, Estrada García J. Ectopic Cushing syndrome: report of 9 cases. Endocrinol Diabetes Nutr 2018; 65: 255-264.
24.
Jung JG, Lee KT, Woo YS, Lee JK, Lee KH, Jang KT, Rhee JC. ehavior of small, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs). Medicine 2015; 94: e983.
25.
Kamilaris CDC, Stratakis CA. Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Front Endocrinol 2019; 10: 339.
26.
Chittiboina P, Lonser RR. Von Hippel-Lindau disease. Handb Clin Neurol 2015; 132: 139-156.
27.
Carrera S, Sancho A, Azkona E, Azkuna J, Lopez-Vivan- co G. Hereditary pancreatic cancer: related syndromes and clinical perspective. Hered Cancer Clin Pract 2017; 15: 9.
28.
Perri G, Prakash LR, Katz MHG. Pancreatic neuroendocrine tumors. Curr Opin Gastroenterol 2019; 35: 468-477.
29.
Portocarrero LKL, Quental KN, Samorano LP, Olivei- ra ZNP, Rivitti-Machado M. Tuberous sclerosis complex: review based on new diagnostic criteria. An Bras Dermatol 2018; 93: 323-331.
30.
Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH. Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management. World J Gastroenterol 2020; 26: 2305-2322.
31.
Tseng CM, Cheng TY, Chen TB, Tien YW, Chen CC, Lin JT, Wang HP. Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors. Oncol Lett 2018; 15: 8951-8958.
32.
Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, Faggiano A. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer 2018; 25: R11-R129.
33.
Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol 2018; 14: 656-669.
34.
Isgrò MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: biochemical and clinical aspects. Adv Exp Med Biol 2015; 867: 125-143.
35.
Oh HJ, Park HY, Kim KH, Park CK, Shin HJ, Lim JH, Kwon YS, Oh IJ, Kim YI, Lim SC, Kim YC, Kim SH, Shin MG. Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer. J Thorac Dis 2016; 8: 2530-2537.
36.
Modlin IM, Kidd M, Malczewska A, Drozdov I, Bodei L, Matar S, Chung KM. The NETest: the clinical utility of multigene blood analysis in the diagnosis and management of neuroendocrine tumors. Endocrinol Metab Clin North Am 2018; 47: 485-504.
37.
Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, Sankowski A, Modlin IM, Kidd M. Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. J Clin Endocrinol Metab 2015; 100: E1437-E1445.
38.
Rizzo FM, Meyer T. Liquid biopsies for neuroendocrine tumors: circulating tumor cells, DNA, and MicroRNAs. Endocrinol Metab Clin North Am 2018; 47: 471-483.
39.
Malczewska A, Kidd M, Matar S, Kos-Kudla B, Modlin IM. Comprehensive assessment of the role of miRNAs as biomarkers in gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 2018; 107: 73-90.
40.
Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology 2018; 72: 168-177.
41.
Vijayvergia N, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ, Engstrom PF. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. Br J Cancer 2016; 115: 564-570.
42.
Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO Grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol 2016; 40: 1192-1202.
43.
Maxwell JE, Howe JR. Imaging in neuroendocrine tumors: an update for the clinician. Int J Endocr Oncol 2015; 2: 159-168.
44.
Scott AT, Howe JR. Evaluation and management of neuroendocrine tumors of the pancreas. Surg Clin North Am 2019; 99: 793-814.
45.
Tirosh A, Kebebew E. The utility of (68)Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. Future Oncol 2018; 14: 111-122.
46.
Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol 2016; 34: 588-596.
47.
Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther 2018; 18: 837-860.
48.
Kann PH. Is endoscopic ultrasonography more sensitive than magnetic resonance imaging in detecting and localizing pancreatic neuroendocrine tumors? Rev Endocr Metab Disord 2018; 19: 133-137.
49.
Zhang IY, Zhao J, Fernandez-Del Castillo C, Braun Y, Razmdjou S, Warshaw AL, Lillemoe KD, Ferrone CR. Operative versus nonoperative management of nonfunctioning pancreatic neuroendocrine tumors. J Gastrointest Surg 2016; 20: 277-283.
50.
Regenet N, Carrere N, Boulanger G, de Calan L, Hu- meau M, Arnault V, Kraimps JL, Mathonnet M, Pes- saux P, Donatini G, Venara A, Christou N, Bachelier P, Hamy A, Mirallié E. Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: a French multicenter study. Surgery 2016; 159: 901-907.
51.
Liu JB, Baker MS. Surgical management of pancreatic neuroendocrine tumors. Surg Clin North Am 2016; 96: 1447-1468.
52.
Clancy TE. Surgical management of pancreatic neuroendocrine tumors. Hematol Oncol Clin North Am 2016; 30: 103-118.
53.
Yu X, Gu J, Wu H, Fu D, Li J, Jin C. Resection of liver metastases: a treatment provides a long-term survival benefit for patients with advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Oncol 2018; 2018: 6273947.
54.
de Mestier L, Zappa M, Hentic O, Vilgrain V, Rusznie- wski P. Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord 2017; 18: 459-471.
55.
Hauser H, Gerson DS, Reidy-Lagunes D, Raj N. Systemic therapies for metastatic pancreatic neuroendocrine tumors. Curr Treat Options Oncol 2019; 20: 87.
56.
Raj N, Reidy-Lagunes D. Systemic therapies for advanced pancreatic neuroendocrine tumors. Hematol Oncol Clin North Am 2016; 30: 119-133.
57.
Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries EGE, Tomassetti P, Hobday T, Pommier R, Oberg K. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol 2016; 34: 3906-3913.
58.
Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Bor- bath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol 2017; 28: 339-343.
59.
Ramage J, Naraev BG, Halfdanarson TR. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. Semin Oncol 2018; 45: 236-248.
60.
Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res 2017; 23: 4617-4624.
61.
Shibuya H, Hijioka S, Sakamoto Y, Ito T, Ueda K, Komo- to I, Kobayashi N, Kudo A, Yasuda H, Miyake H, Arita J, Kiritani S, Ikeda M, Imaoka H, Ueno M, Kobaya- shi S, Furuta M, Nagashio Y, Murohisa G, Aoki T, Matsumoto S, Motoya M, Azemoto N, Itakura J, Horigu- chi S, Yogi T, Kawagoe T, Miyaoka Y, Imamura F, Sen- ju M, Arioka H, Hara K, Imamura M, Okusaka T. Multi- center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy. Cancer Chemother Pharmacol 2018; 82: 661-668.
62.
de Mestier L, Walter T, Evrard C, de Boissieu P, Hentic O, Cros J, Tougeron D, Lombard-Bohas C, Rebours V, Hammel P, Ruszniewski P. Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor. Neuroendocrinology 2020; 110: 83-91.
63.
Palmieri LJ, Dermine S, Barré A, Dhooge M, Brezault C, Cottereau AS, Coriat R. Medical treatment of advanced pancreatic neuroendocrine neoplasms. J Clin Med 2020; 9: 1860.
64.
Spada F, Antonuzzo L, Marconcini R, Radice D, Antonuzzo A, Ricci S, Di Costanzo F, Fontana A, Gelsomi- no F, Luppi G, Nobili E, Galdy S, Cella CA, Sonzog- ni A, Pisa E, Barberis M, Fazio N. Oxaliplatin-based chemotherapy in advanced neuroendocrine tumors: clinical outcomes and preliminary correlation with biological factors. Neuroendocrinology 2016; 103: 806-814.
65.
Sampedro-Núñez M, Serrano-Somavilla A, Adrados M, Cameselle-Teijeiro JM, Blanco-Carrera C, Cabezas-Agricola JM, Martínez-Hernández R, Martín-Pérez E, Muñoz de Nova JL, Díaz JÁ, García-Centeno R, Caneiro-Gó- mez J, Abdulkader I, González-Amaro R, Marazuela M. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. Sci Rep 2018; 8: 17812.
66.
da Silva A, Bowden M, Zhang S, Masugi Y, Thorner AR, Herbert ZT, Zhou CW, Brais L, Chan JA, Hodi FS, Rodig S, Ogino S, Kulke MH. Characterization of the neuroendocrine tumor immune microenvironment. Pancreas 2018; 47: 1123-1129.
67.
Roberto GA, Rodrigues CMB, Peixoto RD, Younes RN. Gastric neuroendocrine tumor: a practical literature review. World J Gastrointest Oncol 2020; 12: 850-856.
68.
Gluckman CR, Metz DC. Gastric Neuroendocrine tumors (carcinoids). Curr Gastroenterol Rep 2019; 21: 13.
69.
Corey B, Chen H. Neuroendocrine tumors of the stomach. Surg Clin North Am 2017; 97: 333-343.
70.
Dias AR, Azevedo BC, Alban LBV, Yagi OK, Ramos M, Jacob CE, Barchi LC, Cecconello I, Ribeiro-Jr U, Zilber- stein B. Gastric neuroendocrine tumor: review and update. Arq Bras Cir Dig 2017; 30: 150-154.
71.
Min BH, Hong M, Lee JH, Rhee PL, Sohn TS, Kim S, Kim KM, Kim JJ. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours. Br J Surg 2018; 105: 1480-6.
72.
Crown A, Kennecke H, Kozarek R, Lopez-Aguiar AG, Dillhoff M, Beal EW, Poultsides GA, Makris E, Idrees K, Smith PM, Nathan H, Beems M, Abbott D, Fisher AV, Fields RC, Davidson J, Maithel SK, Rocha FG. Gastric carcinoids: does type of surgery or tumor affect survival? Am J Surg 2019; 217: 937-942.
73.
Ahmed M. Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol 2020; 12: 791-807.
74.
Delle Fave G, O’Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P, Vienna Consensus Conference participants. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 2016; 103: 119-124.
75.
Verbeek WH, Korse CM, Tesselaar ME. GEP-NETs UPDATE: secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers. Eur J Endocrinol 2016; 174: R1-R7.
76.
Zilli A, Arcidiacono PG, Conte D, Massironi S. Clinical impact of endoscopic ultrasonography on the management of neuroendocrine tumors: lights and shadows. Dig Liver Dis 2018; 50: 6-14.
77.
Sato Y, Hashimoto S, Mizuno K, Takeuchi M, Terai S. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol 2016; 22: 6817-6828.
78.
Jiao X, Wang Z, Peng X, Zhang L, Zhou L. Effects of tumor types on treatment strategy formulation and prognostic evaluation of gastric neuroendocrine tumors. Future Oncol 2020; 16: 2197-2207.
79.
Laird AM, Libutti SK. Management of other gastric and duodenal neuroendocrine tumors. Surg Oncol Clin N Am 2020; 29: 253-266.
80.
Jenny HE, Ogando PA, Fujitani K, Warner RR, Divino CM. Laparoscopic antrectomy: a safe and definitive treatment in managing type 1 gastric carcinoids. Am J Surg 2016; 211: 778-782.
81.
Grozinsky-Glasberg S, Alexandraki KI, Angelousi A, Chatzellis E, Sougioultzis S, Kaltsas G. Gastric carcinoids. Endocrinol Metab Clin North Am 2018; 47: 645-660.
82.
Massironi S, Zilli A, Fanetti I, Ciafardini C, Conte D, Peracchi M. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis. Dig Liver Dis 2015; 47: 978-983.
83.
Lloyd KA, Parsons BN, Burkitt MD, Moore AR, Papoutsopoulou S, Boyce M, Duckworth CA, Exarchou K, Ho- wes N, Rainbow L, Fang Y, Oxvig C, Dodd S, Varro A, Hall N, Pritchard DM. Netazepide inhibits expression of pappalysin 2 in type 1 gastric neuroendocrine tumors. Cell Mol Gastroenterol Hepatol 2020; 10: 113-132.
84.
Manfredi S, Walter T, Baudin E, Coriat R, Ruszniewski P, Lecomte T, Laurenty AP, Goichot B, Rohmer V, Ro- quin G, Cojocarasu OZ, Lombard-Bohas C, Lepage C, Morcet J, Cadiot G. Management of gastric neuro-endocrine tumours in a large French national cohort (GTE). Endocrine 2017; 57: 504-511.
85.
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pa- caud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kul- ke MH, Pavel ME; the RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387: 968-977.
86.
Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther 2015; 9: 5075-5086.
87.
Schmocker RK, Wright MJ, Ding D, Javed AA, Came- ron JL, Lafaro K, Burns WR, He J, Wolfgang CL, Burk- hart RA. Duodenal, ampullary, and pancreatic neuroendocrine tumors: Oncologic outcomes are driven by tumor biology and tissue of origin. J Surg Oncol 2021; 123: 416-424.
88.
Rossi RE, Rausa E, Cavalcoli F, Conte D, Massironi S. Duodenal neuroendocrine neoplasms: a still poorly recognized clinical entity. Scand J Gastroenterol 2018; 53: 835-842.
89.
Gamboa AC, Liu Y, Lee RM, Zaidi MY, Staley CA, Ko- oby DA, Winer JH, Shah MM, Russell MC, Cardona K, Maithel SK. Duodenal neuroendocrine tumors: somewhere between the pancreas and small bowel? J Surg Oncol 2019; 120: 1293-1301.
90.
Vanoli A, La Rosa S, Klersy C, Grillo F, Albarello L, Inza- ni F, Maragliano R, Manca R, Luinetti O, Milione M, Doglioni C, Rindi G, Capella C, Solcia E. Four neuroendocrine tumor types and neuroendocrine carcinoma of the duodenum: analysis of 203 cases. Neuroendocrinology 2017; 104: 112-125.
91.
Massironi S, Campana D, Partelli S, Panzuto F, Rossi RE, Faggiano A, Brighi N, Falconi M, Rinzivillo M, Fave GD, Colao AM, Conte D. Heterogeneity of duodenal neuroendocrine tumors: an Italian multi-center experience. Ann Surg Oncol 2018; 25: 3200-3206.
92.
Niederle B, Selberherr A, Bartsch D, Brandi ML, Do- herty GM, Falconi M, Goudet P, Halfdanarson TR, Ito T, Jen- sen RT, Larghi A, Lee L, Öberg K, Pavel M, Perren A, Sadowski SM, Tonelli F, Triponez F, Valk GD, O’To- ole D, Scott-Coombes D, Thakker RV, Thompson GB, Treglia G, Wiedenmann B. Multiple endocrine neoplasia type 1 (MEN1) and the pancreas – diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome – An International Consensus Statement. Neuroendocrinology 2020; 111: 609-630.
93.
Lee L, Ramos-Alvarez I, Ito T, Jensen RT. Insights into effects/risks of chronic hypergastrinemia and lifelong PPI treatment in man based on studies of patients with Zollinger-Ellison syndrome. Int J Mol Sci 2019; 20: 5128.
94.
Chin JL, O’Toole D. Diagnosis and management of upper gastrointestinal neuroendocrine tumors. Clin Endosc 2017; 50: 520-529.
95.
Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of gastrointestinal neuroendocrine tumors. Clin Med Insights Endocrinol Diabetes 2019; 12: 1179551419884058.
96.
Nießen A, Bergmann F, Hinz U, Schimmack S, Hackert T, Büchler MW, Strobel O. Surgical resection for duodenal neuroendocrine neoplasia: outcome, prognostic factors and risk of metastases. Eur J Surg Oncol 2020; 46: 1088-1096.
97.
Dong DH, Zhang XF, Lopez-Aguiar AG, Poultsides G, Rocha F, Weber S, Fields R, Idrees K, Cho C, Spolvera- to G, Maithel SK, Pawlik TM. Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy. J Surg Oncol 2020; 122: 442-449.
98.
Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knig- ge U, Öberg K, Pavel M, Perren A, Toumpanakis C, Connor JO, O’Toole D, Krenning E, Reed N, Kianmanesh R, Vienna Consensus Conference participants. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology 2016; 103: 125-138.
99.
Byrne RM, Pommier RF. Small bowel and colorectal carcinoids. Clin Colon Rectal Surg 2018; 31: 301-8.
100.
Moris D, Ntanasis-Stathopoulos I, Tsilimigras DI, Va- gios S, Karamitros A, Karaolanis G, Griniatsos J, Papalampros A, Papaconstantinou I, Glantzounis GK, Spartalis E, G Blazer 3rd D, Felekouras E. Update on surgical management of small bowel neuroendocrine tumors. Anticancer Res 2018; 38: 1267-1278.
101.
Milione M, Parente P, Grillo F, Zamboni G, Mastracci L, Capella C, Fassan M, Vanoli A. Neuroendocrine neoplasms of the duodenum, ampullary region, jejunum and ileum. Pathologica 2021; 113: 12-18.
102.
Bösch F, Bruewer K, D’Anastasi M, Ilhan H, Knoesel T, Pratschke S, Thomas M, Rentsch M, Guba M, Werner J, Angele MK. Neuroendocrine tumors of the small intestine causing a desmoplastic reaction of the mesentery are a more aggressive cohort. Surgery 2018; 164: 1093-1099.
103.
Laskaratos FM, Rombouts K, Caplin M, Toumpana- kis C, Thirlwell C, Mandair D. Neuroendocrine tumors and fibrosis: an unsolved mystery? Cancer 2017; 123: 4770-4790.
104.
Luis SA, Pellikka PA. Carcinoid heart disease: diagnosis and management. Best Pract Res Clin Endocrinol Metab 2016; 30: 149-158.
105.
Clift AK, Kidd M, Bodei L, Toumpanakis C, Baum RP, Oberg K, Modlin IM, Frilling A. Neuroendocrine neoplasms of the small bowel and pancreas. Neuroendocrinology 2020; 110: 444-476.
106.
Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, van Dijkum EJMN, Ulrich-Frank P, Pas- cher A, Ramage J, Reed N, Ruszniewski P, Scoazec JY, Toumpanakis C, Kianmanesh R, Falconi M, Antibes Consensus Conference participants. ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology 2017; 105: 255-265.
107.
Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O’Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bas- hir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 2017; 46: 707-714.
108.
Daskalakis K, Tsolakis AV. Upfront surgery of small intestinal neuroendocrine tumors. Time to reconsider? World J Gastroenterol 2018; 24: 3201-3203.
109.
Ejaz A, Reames BN, Maithel S, Poultsides GA, Bauer TW, Fields RC, Weiss MJ, Marques HP, Aldrighetti L, Paw- lik TM. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi- institutional analysis. HPB 2018; 20: 277-284.
110.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O’Dorisio TM, Baum RP, Kulkarni HR, Ca- plin M, Lebtahi R, Hobday T, Delpassand E, Van Cut- sem E, Benson Al, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Sierra ML, Santoro P, Thevenet T, Erion JL, Rusznie- wski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376: 125-135.
111.
Ford MM. Neuroendocrine tumors of the colon and rectum. Dis Colon Rectum 2017; 60: 1018-1020.
112.
Warsinggih, Liliyanto, Prihantono, Ariani GDW, Faruk M. Colorectal neuroendocrine tumors: a case series. Int J Surg Case Rep 2020; 72: 411-417.
113.
Kooyker AI, Verbeek WH, van den Berg JG, Tesselaar ME, van Leerdam ME. Change in incidence, characteristics and management of colorectal neuroendocrine tumours in the Netherlands in the last decade. United European Gastroenterol J 2020; 8: 59-67.
114.
Sano Y, Tanaka S, Kudo SE, Saito S, Matsuda T, Wada Y, Fujii T, Ikematsu H, Uraoka T, Kobayashi N, Nakamu- ra H, Hotta K, Horimatsu T, Sakamoto N, Fu Ki, Tsuru- ta O, Kawano H, Kashida H, Takeuchi Y, Machida H, Kusaka T, Yoshida N, Hirata I, Terai T, Yamano HO, Kane- ko K, Nakajima T, Sakamoto T, Yamaguchi Y, Tamai N, Nakano N, Hayashi N, Oka S, Iwatate M, Ishikawa H, Murakami Y, Yoshida S, Saito Y. Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Dig Endosc 2016; 28: 526-533.
115.
Moris D, Tsilimigras DI, Vagios S, Ntanasis-Stathopou- los I, Karachaliou GS, Papalampros A, Alexandrou A, Bla- zer DG, Felekouras E. Neuroendocrine neoplasms of the appendix: a review of the literature. Anticancer Res 2018; 38: 601-611.
116.
Wang ZJ, An K, Li R, Shen W, Bao MD, Tao JH, Chen JN, Mei SW, Shen HY, Ma YB, Zhao FQ, Wei FZ, Liu Q. Analysis of 72 patients with colorectal high-grade neuroendocrine neoplasms from three Chinese hospitals. World J Gastroenterol 2019; 25: 5197-5209.
117.
Koenig A, Krug S, Mueller D, Barth PJ, Koenig U, Scharf M, Ellenrieder V, Michl P, Moll R, Homayunfar K, Kann PH, Stroebel P, Gress TM, Rinke A. Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms. PLoS One 2017; 12: e0188876.
118.
Luong TV, Nisa Z, Watkins J, Hayes AR. Should immunohistochemical expression of mismatch repair (MMR) proteins and microsatellite instability (MSI) analysis be routinely performed for poorly differentiated colorectal neuroendocrine carcinomas? Endocrinol Diabetes Metab Case Rep 2020; 2020: 20-0058.
119.
Ni SJ, Sheng WQ, Du X. Pathologic research update of colorectal neuroendocrine tumors. World J Gastroenterol 2010; 16: 1713-1719.
120.
Olevian DC, Nikiforova MN, Chiosea S, Sun W, Baha- ry N, Kuan SF, Pai RK. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival. Hum Pathol 2016; 49: 124-134.
121.
Ikeda K, Kojima M, Saito N, Sakuyama N, Koushi K, Watanabe T, Sugihara K, Akimoto T, Ito M, Ochiai A. Current status of the histopathological assessment, diagnosis, and reporting of colorectal neuroendocrine tumors: a web survey from the Japanese Society for Cancer of Colon and Rectum. Pathol Int 2016; 66: 94-101.
122.
Kang JH, Kim SH, Han JK. Poorly-differentiated colorectal neuroendocrine tumour: CT differentiation from well-differentiated neuroendocrine tumour and poorly-differentiated adenocarcinomas. Eur Radiol 2017; 27: 3867-3876.
123.
Takeda K, Kudo SE, Misawa M, Mori Y, Yamano M, Inoue H. Endocytoscopic findings of colorectal neuroendocrine tumors (with video). Endosc Int Open 2018; 6: E589-E593.
124.
Maryański J, Cyran-Chlebicka A, Szczepankiewicz B, Cebulski W, Słodkowski M, Wroński M. Surgical treatment of extra-appendiceal colorectal neuroendocrine tumors. Pol Przegl Chir 2018; 90: 7-12.
125.
Fields AC, Lu P, Vierra BM, Hu F, Irani J, Bleday R, Goldberg JE, Nash GM, Melnitchouk N. Survival in patients with high-grade colorectal neuroendocrine carcinomas: the role of surgery and chemotherapy. Ann Surg Oncol 2019; 26: 1127-1133.
126.
Öberg K. Medical therapy of gastrointestinal neuroendocrine tumors. Visc Med 2017; 33: 352-356.
127.
Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A. BRAF(V600E) mutation: a promising target in colorectal neuroendocrine carcinoma. Int J Cancer 2019; 144: 1379-1390.
128.
Ye C, Yuan CH, Li G, Zheng L, Xiu DR. Gastroenteropancreatic neuroendocrine tumor microenvironment and related therapy. Zhonghua Wai Ke Za Zhi 2019; 57: 866-871.
129.
Kotagal M, von Allmen D. Gastroenteropancreatic neuroendocrine tumors. Semin Pediatr Surg 2020; 29: 150928.
130.
Langbein T, Weber WA, Eiber M. Future of theranostics: an outlook on precision oncology in nuclear medicine. J Nucl Med 2019; 60 (Suppl 2): 13s-19s.
131.
Uri I, Grozinsky-Glasberg S. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol 2018; 4: 16.
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
